AIMS Neuroscience is an esteemed open-access journal published by the American Institute of Mathematical Sciences (AIMS), dedicated to advancing the field of neuroscience since its inception in 2014. With a robust ISSN of 2373-8006 and an E-ISSN of 2373-7972, this journal aims to provide a platform for innovative research and scholarly discourse that spans the diverse and dynamic landscape of the neuroscience discipline. As of 2023, it holds a respectable Q3 category ranking in the miscellaneous neuroscience field and ranks #65 out of 113 in general neuroscience according to Scopus, positioning it in the 42nd percentile for impact. AIMS Neuroscience encompasses a broad scope of topics, from neurobiology and cognitive neuroscience to computational models and neuroengineering, making it a vital resource for researchers, professionals, and students alike. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and knowledge sharing within the global neuroscience community.

Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

Clinical and Experimental Gastroenterology is a prestigious Open Access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of gastroenterology through rigorous research and innovative insights. With its ISSN 1178-7023, the journal has established a significant presence since its inception in 2008 and has been actively contributing to the academic landscape from New Zealand. The journal has attained a commendable Q2 rank in the Gastroenterology category as of 2023, placing it in the upper-tier percentile of similar journals. It currently ranks #57 out of 167 in the Scopus database, highlighting its relevance and impact in the field at the 66th percentile. Encompassing a wide range of topics within gastroenterology, the journal aims to foster discussion and disseminate findings that enhance clinical practices and patient care. Researchers, healthcare professionals, and students alike will find this journal an invaluable resource for cutting-edge research and developments in gastrointestinal health.

METABOLIC BRAIN DISEASE, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal dedicated to advancing our understanding of the metabolic processes impacting brain health and disease. Established in 1986 and set to continue until 2024, this journal encompasses a wide range of interdisciplinary research that intersects the fields of Biochemistry, Cellular and Molecular Neuroscience, and Neurology, as evidenced by its notable quartile placements in Q2 and Q3 for 2023. With an ISSN of 0885-7490 and an E-ISSN of 1573-7365, it serves as a vital resource for researchers and practitioners aiming to deepen their insights into cerebral metabolic disorders and their implications. Although currently not an Open Access option, its rigorous peer-review process ensures that high-quality, impactful research reaches its audience. Showcasing a significant rank within the top percentile of its categories, METABOLIC BRAIN DISEASE is instrumental in shaping the future of neurological research and clinical applications.

Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

BMC NEUROSCIENCE is a prominent open access journal dedicated to the dissemination of high-quality research within the dynamic and rapidly evolving field of neuroscience. Published by BMC, a well-respected leader in open access publishing, this journal facilitates the free exchange of knowledge since its inception in 2000. With the ISSN 1471-2202, BMC NEUROSCIENCE aims to address the diverse interests of the neuroscience community by covering a broad spectrum of topics, ranging from cellular and molecular neuroscience to general neurological studies, thus appealing to researchers, professionals, and students alike. Although it currently holds a Q4 ranking in Cellular and Molecular Neuroscience and a Q3 rank in miscellaneous Neuroscience categories, its commitment to advancing the understanding of brain function and disorders remains steadfast. The journal features a user-friendly Open Access model, ensuring that critical research findings are readily accessible to everyone, fostering collaboration and innovation in the field. As the journal continues to evolve towards its convergence years of 2024, it aspires to enhance its impact and global reach, making it a valuable resource for anyone interested in advancing neuroscience research.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

NEUROCHEMISTRY INTERNATIONAL, published by Pergamon-Elsevier Science Ltd, offers a premier platform for researchers and professionals in the realms of cell biology and cellular and molecular neuroscience. Established in 1980 and continuing its passion for advancing the field, this esteemed journal enhances scientific collaboration with a notable 2023 Q2 ranking in both relevant categories, placing it among the top-tier publications in its discipline with a Scopus rank of 23/97 for Cellular and Molecular Neuroscience. With its focus on groundbreaking research, the journal provides a wealth of vital data and insights that drive forward our understanding of neurochemistry and its implications in health and disease. While not an Open Access journal, NEUROCHEMISTRY INTERNATIONAL is integral for professionals, academics, and students aiming to stay at the forefront of neurobiological research innovations, making significant contributions to both academia and clinical applications.

Journal of Alzheimer's Disease, published by IOS Press, stands as a pivotal resource in the fight against Alzheimer's and related neurodegenerative disorders. With an ISSN of 1387-2877 and an E-ISSN of 1875-8908, this esteemed journal has evolved since its inception in 1998, providing a vital platform for academic research and clinical practice in the realms of Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Ranked in the Q1 category across several disciplines, including Clinical Psychology and Geriatrics, this journal not only highlights significant advancements in understanding Alzheimer's disease but also fosters interdisciplinary dialogue among researchers, healthcare professionals, and policymakers. Boasting robust Scopus rankings—such as 49th in Clinical Psychology and 29th in Geriatrics—this journal is committed to disseminating high-quality research that informs both therapeutic strategies and public health initiatives. The Journal of Alzheimer's Disease is an essential resource for anyone dedicated to exploring the complexities of cognitive decline and enhancing care for affected individuals.

CURRENT OPINION IN NEUROLOGY is a premier academic journal dedicated to providing insightful overviews and critical analyses across all areas of neurology and clinical neurology. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an impressive impact factor, highlighting its influence and relevance in the field—positioning it in the Q1 category for both neurology and clinical neurology as of 2023. With its comprehensive coverage, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to stay abreast of the latest developments, trends, and breakthroughs in neurological science and practice. Though not open access, articles are available via institutional subscriptions or individual purchase, ensuring that vital research remains accessible to a wide audience. Covering research from its inception in 1993 to ongoing studies in 2024, CURRENT OPINION IN NEUROLOGY stands out as an essential platform for disseminating knowledge and fostering dialogue within the dynamic and evolving landscape of neurology.